AL Amyloidosis is a plasma cell disorder characterized by the aggregation and deposition of insoluble amyloid fibrils derived from misfolding of monoclonal immunoglobulin light chains usually produced...
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
The documentation surrounding AL amyloidosis is limited primarily due to its rarity, affecting fewer than 10,000 people in the U.S. This scarcity results in fewer systematic clinical studies and a lack of comprehensive phenotype documentation. Additionally, the complexity of the disease and its overlap with other conditions complicate the clinical characterization.
For managing AL amyloidosis, it is essential to seek care from a hematologist with expertise in plasma cell disorders. You may also want to explore clinical trials, as they can provide access to cutting-edge therapies. Consider reaching out to organizations like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional resources. While there are currently no identified patient organizations specific to AL amyloidosis, participating in clinical trials may also offer insights into the condition's natural history.
There are currently 82 active clinical trials investigating various aspects of AL amyloidosis. Notable orphan drugs designated for this condition include Autologous T cells expressing anti-B cell maturation agent chimeric antigen receptor and N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=AL%20amyloidosis.
Actionable guidance for navigating care for AL amyloidosis
For managing AL amyloidosis, it is essential to seek care from a hematologist with expertise in plasma cell disorders. You may also want to explore clinical trials, as they can provide access to cutting-edge therapies. Consider reaching out to organizations like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional resources. While there are currently no identified patient organizations specific to AL amyloidosis, participating in clinical trials may also offer insights into the condition's natural history.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 5 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.